223 related articles for article (PubMed ID: 15757488)
1. GABA and glutamate systems as therapeutic targets in depression and mood disorders.
Kendell SF; Krystal JH; Sanacora G
Expert Opin Ther Targets; 2005 Feb; 9(1):153-68. PubMed ID: 15757488
[TBL] [Abstract][Full Text] [Related]
2. A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Wilkinson ST; Sanacora G
Drug Discov Today; 2019 Feb; 24(2):606-615. PubMed ID: 30447328
[TBL] [Abstract][Full Text] [Related]
3. Trial watch: phase II boost for glutamate-targeted antidepressants.
Flight MH
Nat Rev Drug Discov; 2013 Dec; 12(12):897. PubMed ID: 24287771
[No Abstract] [Full Text] [Related]
4. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments.
Krystal JH; Sanacora G; Blumberg H; Anand A; Charney DS; Marek G; Epperson CN; Goddard A; Mason GF
Mol Psychiatry; 2002; 7 Suppl 1():S71-80. PubMed ID: 11986998
[TBL] [Abstract][Full Text] [Related]
5. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action.
Sanacora G; Saricicek A
CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):127-40. PubMed ID: 17430150
[TBL] [Abstract][Full Text] [Related]
6. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders.
Sanacora G; Treccani G; Popoli M
Neuropharmacology; 2012 Jan; 62(1):63-77. PubMed ID: 21827775
[TBL] [Abstract][Full Text] [Related]
7. Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression.
Benson C; Mifflin K; Kerr B; Jesudasan SJ; Dursun S; Baker G
Mod Trends Pharmacopsychiatry; 2015; 30():67-79. PubMed ID: 26437459
[TBL] [Abstract][Full Text] [Related]
8. Advances in novel molecular targets for antidepressants.
Wang Q; Dwivedi Y
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110041. PubMed ID: 32682872
[TBL] [Abstract][Full Text] [Related]
9. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders.
Femenía T; Gómez-Galán M; Lindskog M; Magara S
Brain Res; 2012 Oct; 1476():58-70. PubMed ID: 22541166
[TBL] [Abstract][Full Text] [Related]
10. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments.
Duman RS; Sanacora G; Krystal JH
Neuron; 2019 Apr; 102(1):75-90. PubMed ID: 30946828
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment.
Siegel AN; Rodrigues N; Nasri F; Wilkialis L; Lipsitz O; Lee Y; Gill H; Subramaniapillai M; Phan L; Majeed A; Lui LMW; Rashidian H; Ho R; Toma S; Goldstein BI; Mansur RB; McIntyre RS; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110032. PubMed ID: 32634540
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptors in the control of mood disorders.
Witkin JM; Marek GJ; Johnson BG; Schoepp DD
CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):87-100. PubMed ID: 17430147
[TBL] [Abstract][Full Text] [Related]
13. Preclinical models: status of basic research in depression.
Nestler EJ; Gould E; Manji H; Buncan M; Duman RS; Greshenfeld HK; Hen R; Koester S; Lederhendler I; Meaney M; Robbins T; Winsky L; Zalcman S
Biol Psychiatry; 2002 Sep; 52(6):503-28. PubMed ID: 12361666
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance spectroscopy studies of GABA in neuropsychiatric disorders.
Chang L; Cloak CC; Ernst T
J Clin Psychiatry; 2003; 64 Suppl 3():7-14. PubMed ID: 12662128
[TBL] [Abstract][Full Text] [Related]
15. Evolution of neurotransmitter gamma-aminobutyric acid, glutamate and their receptors.
Gou ZH; Wang X; Wang W
Dongwuxue Yanjiu; 2012 Dec; 33(E5-6):E75-81. PubMed ID: 23266985
[TBL] [Abstract][Full Text] [Related]
16. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression.
Sanacora G; Gueorguieva R; Epperson CN; Wu YT; Appel M; Rothman DL; Krystal JH; Mason GF
Arch Gen Psychiatry; 2004 Jul; 61(7):705-13. PubMed ID: 15237082
[TBL] [Abstract][Full Text] [Related]
17. From synapse to nucleus: novel targets for treating depression.
Covington HE; Vialou V; Nestler EJ
Neuropharmacology; 2010; 58(4-5):683-93. PubMed ID: 20018197
[TBL] [Abstract][Full Text] [Related]
18. The missing link between clinical endpoints and drug targets in depression.
Della Pasqua O; Santen GW; Danhof M
Trends Pharmacol Sci; 2010 Apr; 31(4):144-52. PubMed ID: 20117847
[TBL] [Abstract][Full Text] [Related]
19. GPR39 Zn(2+)-sensing receptor: a new target in antidepressant development?
Młyniec K; Singewald N; Holst B; Nowak G
J Affect Disord; 2015 Mar; 174():89-100. PubMed ID: 25490458
[TBL] [Abstract][Full Text] [Related]
20. In vivo evidence for reduced cortical glutamate-glutamine cycling in rats treated with the antidepressant/antipanic drug phenelzine.
Yang J; Shen J
Neuroscience; 2005; 135(3):927-37. PubMed ID: 16154287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
